Skip to main content

Table 4 Selected other outcomes

From: 17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial

 

17-Hydroxyprogesterone Caproate

Placebo

 

(N = 4)

(N = 8)

Maternal Management & Complications

3 (75%)

7 (87.5%)

   Tocolysis in first 48 h

3 (75%)

5 (62.5%)

   Antenatal Corticosteroids

4 (100%) *

8 (100%)

   Cesarean Delivery

3 (75%)

5 (62.5%)

   Preeclampsia or Gestational Hypertension

0

1 (12.5%)

   Gestational Diabetes

0

2 (25%)

   Chorioamnionitis

1 (25%)

1 (12.5%)

   Sepsis

0

0

Neonatal Outcomes

   Birthweight, gms

1328 ± 547

1288 ± 525

   Total Hospital Stay, Days

42 ± 23

57 ± 48

   NICU Stay, Days

42 ± 23

56 ± 48

   Newborns with Congenital Anomaly**

1 (25%)

3 (37.5%)

   Adverse Events Not Tabulated Elsewhere***

0

1 (12.5%)

  1. Data expressed as Mean ± SD or N (%)
  2. NICU = Neonatal Intensive Care Unit
  3. * One patient had received antenatal corticosteroids before PROM.
  4. ** One newborn in 17P group had ventriculoseptal defect and patent foramen ovale. Newborns with anomalies in the placebo group were 1 with bilateral inguinal hernias and hypospadias, 1 with unilateral inguinal hernia, and 1 with umbilical hernia.
  5. *** One newborn had congenital lobar emphysema